As the international cancer week is coming by, The 4th International Congress of Traditional Chinese Medicine and Integrated TCM-WM Oncology & The 13th National Academic Congress of Integrative TCM-WM Oncology Conference in Nanning, Guangxi was held successfully, just before the week of Internationl Cancer Week, of which was organized by the members of the Community of Oncologist by the Traditional Chinese Medicine, and the Anti-Cancer Association tumor Traditional Medicine Committee.

 

Shenzhen ZMKS Biotechnology Company, as the exclusive service provider of "ACTL Tumor Cell targeting therapy" was cordially invited to attend this conference. Professor Yong Liu, the founder of ACTLTM, from The Stanford University School of Medicine Cancer Center in US, has presented a comprehensive academic lecture with the technology mechanisim background of the ACTLTM tumor cell targeting therapy, and it has earned well enough recognitions from the experts in the field.  mechanism background of the ACTLTM tumor cell targeting therapy, and it has earned well enough recognitions from the experts in the field.

  

 

As the 4th cancer treatment of the world, ACLTTM tumor cell targeted therapy is the breakthroughs and revolutionary of the development of cancer treatment, it's leading of the development direction of cancer treatment. The Canadian scientist, United States Medical Association and the United States National Academy of Sciences, Academician Professor Ralph M. Steinman who awarded with "dendritic cells and its role in the Adaptive immune system discovery" for 2011 Nobel Medicine Prize. Prof. Liu's ACTLTM was developed based on the DC cell targeting therapy.